Arthritis News and Research

Latest Arthritis News and Research

Twelve residents receive one-year fellowship grant to study medical dermatology

Twelve dermatology residents from leading medical schools around the country each received a $40,000, one-year fellowship grant to study medical dermatology. The fellowships, awarded by the National Psoriasis Foundation, provide support to eligible institutions to develop and enhance opportunities for physicians training for careers in medical dermatology.

1 Jul 2010

Advancements in total hip replacement procedure make young patients opt for surgery

Traditionally, total hip replacement surgery was performed on the elderly, but these days, advancements in the procedure have patients opting for the surgery much earlier in life.

1 Jul 2010

CBio achieves recruitment milestone in XToll clinical trial

Australian drug development company CBio Limited today announced the achievement of a recruitment milestone in its clinical trial of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis.

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Calistoga Pharmaceuticals closes $40 million Series C financing

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced it has closed a $40 million Series C financing. The financing was led by Quogue Capital, LLC along with existing investors Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and new investor Latterell Venture Partners.

30 Jun 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Preliminary findings show RA drug reduces brain damage in stroke patients

A drug used to treat rheumatoid arthritis also reduces the damage a stroke inflicts on the brain according to lab research and preliminary findings from a clinical trial of stroke patients. The results open the door for a larger clinical study to refine the drug anakinra's use as an effective therapy for victims of stroke.

From The University of Manchester 30 Jun 2010

Health experts to discuss OA prevention and treatment strategies at international Arthritis Summit

Hospital for Special Surgery plans to host a two-day international Osteoarthritis Summit in June 2011.

30 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

An immune cell known to cause chronic inflammation in autoimmune disorders has been identified as a possible culprit in low back pain associated with herniated discs, according to doctors at Duke University Medical Center.

29 Jun 2010

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 annual meeting in Boston, MA.

29 Jun 2010

ITMTX treatment effective in late stages/progressive forms of MS: Study

The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.

28 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Cartilage loss plays a role in development of OA, study says

A recent study determined that bone area predicted the development of medial (inner side) and lateral (outer side) knee cartilage damage and loss of medial cartilage volume. Subchondral bone mineral density (BMD) was associated with medial defect development but not cartilage loss. Researchers believe subchondral bone changes and loss of cartilage contribute to the development of osteoarthritis (OA).

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Arthritis News and Research

Latest Arthritis News and Research

Twelve residents receive one-year fellowship grant to study medical dermatology

Advancements in total hip replacement procedure make young patients opt for surgery

CBio achieves recruitment milestone in XToll clinical trial

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Bortezomib may offer hope for treating inflammatory diseases: New research

Calistoga Pharmaceuticals closes $40 million Series C financing

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Preliminary findings show RA drug reduces brain damage in stroke patients

Health experts to discuss OA prevention and treatment strategies at international Arthritis Summit

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

AlphaRx regains all rights to Indaflex from Cypress Bioscience

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Study implicates cytokine molecule IL-17 in low back pain associated with herniated discs

Avila's AVL-292 demonstrates disease-modifying effects in prophylactic, therapeutic models of rheumatoid arthritis

ITMTX treatment effective in late stages/progressive forms of MS: Study

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Cartilage loss plays a role in development of OA, study says

ADVANCE study provides new insights into the management of SHPT in CKD patients

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Arthritis News and Research

Latest Arthritis News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in